CervoMed Inc.
CRVOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. At a $26.8M market cap, CervoMed Inc. ranks as a micro-cap company within healthcare. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Market Cap
$26.8M
Beta
-4.42
P/E (TTM)
—
P/E (Fwd)
-1.25
EPS (TTM)
$-3.36
EPS (Fwd)
$-2.32
ROE
-132.8%
ROA
-72.4%
Cash
$12.9M
Total Debt
$0
Free CF
-$16.3M
52W Change
-65.0%
Annual Financials
Cash vs Debt
Where CRVO stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CRVO finished 35.56% below its 150-day moving average ($4.78) and 44.70% below its 200-day moving average ($5.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRVO overbought or oversold?
At the July 15, 2026 close, CRVO's RSI(14) was 39.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
CervoMed Inc. reports $12.9M in cash and $0 in total debt. Free cash flow is running at -$16.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -132.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, CervoMed Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CervoMed Inc.'s trajectory.